The largest database of trusted experimental protocols

Cilastatin

Manufactured by Merck Group
Sourced in United States, Canada

Cilastatin is a pharmaceutical compound developed by Merck Group. It is a metabolic inhibitor that works by blocking the breakdown of certain antibiotics in the body, thereby increasing their effectiveness and therapeutic potential. Cilastatin is commonly used in combination with other medications to enhance their pharmacokinetic properties and improve patient outcomes.

Automatically generated - may contain errors

6 protocols using cilastatin

1

Sepsis Treatment with Cit-AuNP and Antibiotics

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mice were daily followed for 10 days to measure the survival rate after induction of sepsis. Cit-AuNP or saline was injected twice, 2 and 24 h after induction of sepsis, the same protocol and dose described in the " Gold nanoparticle treatment" Section. A group of mice was concomitantly IV treated with an antibiotic regimen composed of imipenem and cilastatin (0.3 mg and 0.6 mg per animal, respectively) (Sigma-Aldrich) injected twice a day for three days (through the femoral vein), starting 2 h after induction of sepsis and at 12 h intervals afterwards, to determine whether any drug interaction would occur compared to a group only treated with imipenem and cilastatin. This antibiotic regimen was previously described in [84 (link)], and slightly modified. Alternate femoral veins were used every treatment time.
+ Open protocol
+ Expand
2

Solubility Enhancement and Combinatorial Antibiotic Studies

Check if the same lab product or an alternative is used in the 5 most similar protocols
TP0586532 was synthesized by Taisho Pharmaceutical Co, Ltd., (Saitama, Japan). The drug was dissolved in dimethyl sulfoxide (for the in vitro studies) or 11 w/v% sulfobutylether-β-cyclodextrin sodium salt (11 v/w% SBE-β-CD, for the in vivo studies). Ceftazidime was purchased from Sigma-Aldrich (St. Louis, MO). Ciprofloxacin was purchased from FUJIFILM Wako Pure Chemical Corporation (Osaka, Japan). Meropenem was purchased from Sumitomo Dainippon Pharma Co., Ltd. (Osaka, Japan) and U.S. Pharmacopeial Convention (Rockville, MD). Cilastatin was purchased from Sigma-Aldrich and AvaChem Scientific (San Antonio, TX). Meropenem was combined with Cilastatin at ratio of 1:1 for the in vivo study. Ceftazidime was dissolved in distilled water. Ciprofloxacin and meropenem were dissolved in distilled water (for in vitro studies) or saline (for the in vivo studies). Cilastatin was dissolved in saline.
+ Open protocol
+ Expand
3

Cytotoxicity Evaluation of Chemotherapeutics

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cisplatin was generously supplied by Bristol-Myers Squibb (New York, NY, USA). Gemcitabine, carboplatin, oxaliplatin, pemetrexed and cilastatin were purchased from Sigma-Aldrich (St. Louis, MO, USA).
CT26 colon adenocarcinoma cells from BALB/c mice, HK-2 human proximal tubule epithelial cells, and the A549, HCC827 and H1975 human pulmonary adenocarcinoma cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA). S2 and Lu85 human pulmonary small-cell carcinoma cells were kindly gifted by Dr. S. Shu (Cleveland Clinic, OH, USA). All cell lines were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 10% CO2 at 37 °C. Whole human kidney lysate was obtained from Novus Biologicals (Littleton, CO, USA).
+ Open protocol
+ Expand
4

Gentamicin-Texas Red Conjugate Trafficking and Otoprotection

Check if the same lab product or an alternative is used in the 5 most similar protocols
GTTR was generated and purified, as previously described (14 (link)). Gentamicin (LE1046, Accel Pharmtech) was mixed with Texas Red succinimidyl esters (T20175, Invitrogen). The conjugate was separated from unconjugated gentamicin and unreacted Texas Red by C-18 column based reversed-phase chromatography. Soluble Texas Red was used as a control (S7635, Sigma-Aldrich). To block megalin receptors, cilastatin (C5743, Sigma-Aldrich) was applied. 1× PBS was used for the vehicle.
For in vivo imaging, GTTR or Texas Red was i.p. (100 mg/kg) or i.v. (10 mg/kg) injected into mice. Intravenous injection of 30 mg/kg cilastatin was followed by a single injection of GTTR (i.v. 10 mg/kg).
For investigations of otoprotection from cilastatin, either saline or cilastatin (360 mg/kg) was systematically administrated with i.p. injection. After 30 min, either saline or cilastatin (180 mg/kg) i.p. injection was followed by gentamicin i.p. injection (180 mg/kg). After another 30 min, both groups received a furosemide i.p. injection (100 mg/kg). These injections were repeated daily for 10 d. Note that either cilastatin (540 mg/kg) or saline i.p. injection was preceded 1 d before starting the injections as a pretreatment.
+ Open protocol
+ Expand
5

Antibiotic Delivery System Synthesis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Poly Ɛ-caprolactone (Mn = 45,000), polylactide-co-glycolide (50:50 Mw = 7000–17,000) and didodecyl dimethyl ammonium bromide (DMAB) were obtained from Aldrich-Sigma chemical company, USA. Imipenem and cilastatin (pharmaceutical grade) were kindly gifted from Merck Sharp & Dohme Corp., Canada. All the other chemicals were of analytical grade and used as received. Deionised water (Millipore®, 18.2 MΩ cm) was utilized as the water source in the experimental procedures.
+ Open protocol
+ Expand
6

Albumin Uptake by RPTECs Under Static and Dynamic Conditions

Check if the same lab product or an alternative is used in the 5 most similar protocols
Albumin uptake by RPTECs was determined on cells grown on collagen-coated Transwells under static and dynamic conditions. Cells were incubated with 200 µg/mL albumin-FITC (A9771, Merck) overnight and subsequently washed and fixed. To assess the specificity of the receptor-mediated uptake, some cultures were pretreated overnight with 200 µg/mL of the megalin/cubilin inhibitor cilastatin (SML1283, Merck).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!